Research ArticleNeurodegenerative Disease

A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy

See allHide authors and affiliations

Science Translational Medicine  27 Mar 2019:
Vol. 11, Issue 485, eaat3005
DOI: 10.1126/scitranslmed.aat3005

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A rheostat for tau pathology

Tau inclusions are a prominent feature of many neurodegenerative diseases and are considered to be a potential therapeutic target. Hernandez et al. now report a previously unrecognized pathway leading to tau clearance via the lysosome. Activation of this pathway by inhibiting the enzyme farnesyltransferase blocks the attachment of a neuronal protein, Rhes, to the cell membrane. Farnesyltransferase inhibitors are already in use in human patients for treating cancer. The authors treated a mouse model of tauopathy with one such drug, lonafarnib, and were able to prevent the formation of tau inclusions, decrease microgliosis and brain atrophy, and attenuate behavioral abnormalities.

View Full Text